There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bio-Path Holdings (BPTH) and Fibrocell Science Inc (FCSC) with bullish sentiments.
Bio-Path Holdings (BPTH)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bio-Path Holdings today and set a price target of $28. The company’s shares closed last Monday at $12.18, close to its 52-week low of $1.61.
Chen observed:
“We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -19.7% and a 24.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
Currently, the analyst consensus on Bio-Path Holdings is a Moderate Buy with an average price target of $28.
See today’s analyst top recommended stocks >>
Fibrocell Science Inc (FCSC)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Fibrocell Science Inc today and set a price target of $20. The company’s shares closed last Monday at $1.80.
Pantginis said:
“Valuation and risks to price target achievement. We reiterate our Buy rating, but are lowering our price target to $20 from $22 based on the following factors: (1) adjustment to base year; (2) increasing our projected chance of success for 55%, which places it on par with our projections for Krystal’s KB103, which is also about to enter Phase 3 on positive (3) adjusting our clinical NPV metrics on economics based on the share of payments due Intrexon.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.2% and a 28.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Fibrocell Science Inc is a Moderate Buy with an average price target of $20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
